DDInter1035 DDInter1676
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lenalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Lenalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
Lenalidomide {u} (Compound) binds {v} (Gene) PTGS2
Lenalidomide {u} (Compound) upregulates {v} (Gene) RRP8
Lenalidomide {u} (Compound) downregulates {v} (Gene) GDF15
Lenalidomide {u} (Compound) causes {v} (Side Effect) Cholecystitis
Lenalidomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Lenalidomide (Compound) resembles Thalidomide (Compound)
Lenalidomide (Compound) resembles Pomalidomide (Compound)
Lenalidomide (Compound) treats hematologic cancer (Disease)
Lenalidomide (Compound) binds PTGS2 (Gene)
Lenalidomide (Compound) upregulates RRP8 (Gene)
Lenalidomide (Compound) downregulates GDF15 (Gene)
Lenalidomide (Compound) causes Cholecystitis (Side Effect)
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol